CN Stock MarketDetailed Quotes

002262 Jiangsu Nhwa Pharmaceutical

Watchlist
  • 25.40
  • -0.46-1.78%
Market Closed Dec 13 15:00 CST
25.81BMarket Cap22.03P/E (TTM)

Jiangsu Nhwa Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Total operating revenue
13.39%4.15B
15.13%2.76B
15.16%1.36B
17.28%5.04B
17.17%3.66B
19.95%2.4B
18.76%1.18B
9.22%4.3B
7.89%3.12B
7.30%2B
Operating revenue
13.39%4.15B
15.13%2.76B
15.16%1.36B
17.28%5.04B
17.17%3.66B
19.95%2.4B
18.76%1.18B
9.22%4.3B
7.89%3.12B
7.30%2B
Other operating revenue
----
-13.84%20.84M
----
50.93%65.63M
----
57.57%24.19M
----
163.08%43.49M
----
54.39%15.35M
Total operating cost
12.63%3B
14.65%2.03B
13.97%1.04B
16.47%3.91B
16.38%2.66B
18.76%1.77B
15.57%909.69M
10.65%3.36B
9.08%2.29B
9.88%1.49B
Operating cost
10.67%1.09B
20.59%759.97M
26.18%396.71M
34.24%1.37B
33.67%983.16M
30.36%630.18M
28.47%314.4M
13.72%1.02B
4.31%735.53M
7.08%483.43M
Operating tax surcharges
9.76%54.09M
11.53%36.78M
11.40%18.67M
18.34%68M
17.95%49.28M
24.11%32.98M
17.60%16.76M
6.34%57.46M
6.65%41.78M
5.50%26.57M
Operating expense
13.65%1.25B
6.03%829.72M
3.88%437.03M
4.96%1.74B
1.51%1.1B
9.54%782.57M
8.13%420.69M
3.78%1.65B
7.21%1.08B
8.95%714.4M
Administration expense
17.91%178.67M
21.44%114.89M
-6.60%47.34M
7.55%207.12M
9.84%151.54M
14.99%94.61M
26.90%50.68M
29.75%192.57M
23.58%137.95M
8.31%82.28M
Financial expense
-22.56%-12.17M
-119.81%-8.78M
-152.06%-6.36M
7.33%-19.26M
-72.43%-9.93M
5.48%-4M
-50.77%-2.52M
-98.91%-20.78M
26.42%-5.76M
21.69%-4.23M
-Interest expense (Financial expense)
0.84%3.22M
2.67%2.34M
157.65%1.19M
-15.84%4.16M
216.29%3.19M
214.01%2.28M
7.26%460.24K
-2.20%4.95M
-14.87%1.01M
-10.09%726.54K
-Interest Income (Financial expense)
-16.90%-16.2M
-74.55%-11.59M
-107.29%-8.09M
6.73%-23.81M
-33.49%-13.86M
10.06%-6.64M
-19.09%-3.9M
-44.26%-25.53M
16.06%-10.38M
13.00%-7.38M
Research and development
13.25%435.67M
26.80%301.5M
30.77%143.42M
20.93%549.32M
32.11%384.71M
24.23%237.78M
8.77%109.68M
29.15%454.25M
23.80%291.21M
22.24%191.4M
Credit Impairment Loss
-19.36%-16.04M
3.72%-16.65M
-42.32%-23.72M
-321.55%-15.11M
-110.07%-13.44M
-316.86%-17.29M
-802.53%-16.66M
52.66%-3.58M
21.16%-6.4M
47.76%-4.15M
Asset Impairment Loss
35.99%-12.32M
42.99%-6.6M
19.35%-6.4M
-105.50%-33.27M
-87.72%-19.25M
-181.21%-11.58M
-536.52%-7.94M
54.20%-16.19M
70.92%-10.26M
87.06%-4.12M
Other net revenue
129.25%21.84M
2,927.66%3.24M
-110.81%-15.89M
-17.11%52.86M
-33.98%9.53M
-101.55%-114.53K
-278.53%-7.54M
147.18%63.77M
190.37%14.43M
135.40%7.38M
Invest income
16.25%43.38M
-17.39%20.85M
-28.24%11.39M
40.72%51.04M
26.34%37.31M
71.82%25.24M
475.22%15.87M
0.13%36.27M
12.31%29.53M
-19.48%14.69M
-Including: Investment income associates
26.78%6.85M
135.21%3.43M
-17.93%4.22M
110.15%9.64M
-0.38%5.4M
540,591.14%1.46M
346.32%5.14M
246.03%4.59M
178.76%5.42M
-99.98%269.73
Asset deal income
114.01%30.19K
-4.45%28.99K
-104.45%-1.35K
-60.59%147.23K
-241.40%-215.58K
-80.05%30.34K
--30.34K
255.40%373.54K
625.74%152.45K
8,121.04%152.07K
Other revenue
32.78%6.8M
61.01%5.6M
143.41%2.85M
6.71%50.05M
266.91%5.12M
334.88%3.48M
246.56%1.17M
43.29%46.9M
21.39%1.39M
21.62%800.39K
Operating profit
16.50%1.17B
17.00%732.55M
16.55%304.87M
17.83%1.18B
18.44%1.01B
21.66%626.09M
24.74%261.58M
8.38%1B
8.74%848.89M
6.17%514.63M
Add:Non operating Income
302.70%2.56M
1,610.39%1.84M
278.31%1.82M
166.72%6.75M
-40.39%635.76K
-122.14%-122.09K
-3,940.42%-1.02M
-17.46%2.53M
-10.05%1.07M
-40.60%551.55K
Less:Non operating expense
305.34%21.56M
236.80%13.41M
238.16%6.96M
27.09%20.45M
-8.23%5.32M
3.89%3.98M
42.44%2.06M
22.29%16.09M
-34.05%5.79M
-48.68%3.83M
Total profit
15.15%1.15B
15.92%720.99M
15.95%299.74M
18.06%1.17B
18.55%1B
21.64%621.99M
24.15%258.5M
8.09%989.91M
9.19%844.16M
6.94%511.35M
Less:Income tax cost
15.76%135.86M
21.70%94.42M
5.31%35.1M
22.38%134.4M
8.36%117.36M
14.05%77.58M
55.13%33.33M
-6.74%109.82M
5.75%108.31M
0.87%68.02M
Net profit
15.07%1.02B
15.09%626.57M
17.53%264.64M
17.52%1.03B
20.05%883.41M
22.80%544.41M
20.58%225.17M
10.28%880.09M
9.72%735.85M
7.93%443.32M
Net profit from continuing operation
15.07%1.02B
15.09%626.57M
17.53%264.64M
17.52%1.03B
--883.41M
22.80%544.41M
--225.17M
10.28%880.09M
----
7.93%443.32M
Less:Minority Profit
-60.33%-3.57M
-696.52%-2.35M
71.48%-643.47K
87.05%-2.67M
63.03%-2.23M
92.95%-294.62K
-15.80%-2.26M
-8,547.33%-20.62M
-168.95%-6.02M
-2,340.01%-4.18M
Net profit of parent company owners
15.18%1.02B
15.46%628.92M
16.64%265.28M
15.12%1.04B
19.38%885.64M
21.72%544.7M
20.53%227.43M
12.90%900.71M
10.25%741.87M
8.91%447.5M
Earning per share
Basic earning per share
14.77%1.01
14.81%0.62
13.04%0.26
15.73%1.03
18.92%0.88
22.73%0.54
21.05%0.23
12.66%0.89
10.48%0.74
7.32%0.44
Diluted earning per share
14.77%1.01
14.81%0.62
13.04%0.26
15.73%1.03
18.92%0.88
22.73%0.54
21.05%0.23
12.66%0.89
10.48%0.74
7.32%0.44
Other composite income
-395.00%-6.35M
151.94%2.15M
Other composite income of parent company owners
----
----
----
-395.00%-6.35M
----
----
----
151.94%2.15M
----
----
Total composite income
15.07%1.02B
15.09%626.57M
17.53%264.64M
16.51%1.03B
20.05%883.41M
22.80%544.41M
20.58%225.17M
11.13%882.24M
9.72%735.85M
7.93%443.32M
Total composite income of parent company owners
15.18%1.02B
15.46%628.92M
16.64%265.28M
14.14%1.03B
19.38%885.64M
21.72%544.7M
20.53%227.43M
13.76%902.86M
10.25%741.87M
8.91%447.5M
Total composite income of minority owners
-60.33%-3.57M
-696.52%-2.35M
71.48%-643.47K
87.05%-2.67M
63.03%-2.23M
92.95%-294.62K
-15.80%-2.26M
-8,547.33%-20.62M
-168.95%-6.02M
-2,340.01%-4.18M
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
--
--
Unqualified opinion
--
--
--
Unqualified opinion
--
--
Auditor
--
--
--
Lixin Certified Public Accountants (Special General Partnership)
--
--
--
Lixin Certified Public Accountants (Special General Partnership)
--
--
(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022
Total operating revenue 13.39%4.15B15.13%2.76B15.16%1.36B17.28%5.04B17.17%3.66B19.95%2.4B18.76%1.18B9.22%4.3B7.89%3.12B7.30%2B
Operating revenue 13.39%4.15B15.13%2.76B15.16%1.36B17.28%5.04B17.17%3.66B19.95%2.4B18.76%1.18B9.22%4.3B7.89%3.12B7.30%2B
Other operating revenue -----13.84%20.84M----50.93%65.63M----57.57%24.19M----163.08%43.49M----54.39%15.35M
Total operating cost 12.63%3B14.65%2.03B13.97%1.04B16.47%3.91B16.38%2.66B18.76%1.77B15.57%909.69M10.65%3.36B9.08%2.29B9.88%1.49B
Operating cost 10.67%1.09B20.59%759.97M26.18%396.71M34.24%1.37B33.67%983.16M30.36%630.18M28.47%314.4M13.72%1.02B4.31%735.53M7.08%483.43M
Operating tax surcharges 9.76%54.09M11.53%36.78M11.40%18.67M18.34%68M17.95%49.28M24.11%32.98M17.60%16.76M6.34%57.46M6.65%41.78M5.50%26.57M
Operating expense 13.65%1.25B6.03%829.72M3.88%437.03M4.96%1.74B1.51%1.1B9.54%782.57M8.13%420.69M3.78%1.65B7.21%1.08B8.95%714.4M
Administration expense 17.91%178.67M21.44%114.89M-6.60%47.34M7.55%207.12M9.84%151.54M14.99%94.61M26.90%50.68M29.75%192.57M23.58%137.95M8.31%82.28M
Financial expense -22.56%-12.17M-119.81%-8.78M-152.06%-6.36M7.33%-19.26M-72.43%-9.93M5.48%-4M-50.77%-2.52M-98.91%-20.78M26.42%-5.76M21.69%-4.23M
-Interest expense (Financial expense) 0.84%3.22M2.67%2.34M157.65%1.19M-15.84%4.16M216.29%3.19M214.01%2.28M7.26%460.24K-2.20%4.95M-14.87%1.01M-10.09%726.54K
-Interest Income (Financial expense) -16.90%-16.2M-74.55%-11.59M-107.29%-8.09M6.73%-23.81M-33.49%-13.86M10.06%-6.64M-19.09%-3.9M-44.26%-25.53M16.06%-10.38M13.00%-7.38M
Research and development 13.25%435.67M26.80%301.5M30.77%143.42M20.93%549.32M32.11%384.71M24.23%237.78M8.77%109.68M29.15%454.25M23.80%291.21M22.24%191.4M
Credit Impairment Loss -19.36%-16.04M3.72%-16.65M-42.32%-23.72M-321.55%-15.11M-110.07%-13.44M-316.86%-17.29M-802.53%-16.66M52.66%-3.58M21.16%-6.4M47.76%-4.15M
Asset Impairment Loss 35.99%-12.32M42.99%-6.6M19.35%-6.4M-105.50%-33.27M-87.72%-19.25M-181.21%-11.58M-536.52%-7.94M54.20%-16.19M70.92%-10.26M87.06%-4.12M
Other net revenue 129.25%21.84M2,927.66%3.24M-110.81%-15.89M-17.11%52.86M-33.98%9.53M-101.55%-114.53K-278.53%-7.54M147.18%63.77M190.37%14.43M135.40%7.38M
Invest income 16.25%43.38M-17.39%20.85M-28.24%11.39M40.72%51.04M26.34%37.31M71.82%25.24M475.22%15.87M0.13%36.27M12.31%29.53M-19.48%14.69M
-Including: Investment income associates 26.78%6.85M135.21%3.43M-17.93%4.22M110.15%9.64M-0.38%5.4M540,591.14%1.46M346.32%5.14M246.03%4.59M178.76%5.42M-99.98%269.73
Asset deal income 114.01%30.19K-4.45%28.99K-104.45%-1.35K-60.59%147.23K-241.40%-215.58K-80.05%30.34K--30.34K255.40%373.54K625.74%152.45K8,121.04%152.07K
Other revenue 32.78%6.8M61.01%5.6M143.41%2.85M6.71%50.05M266.91%5.12M334.88%3.48M246.56%1.17M43.29%46.9M21.39%1.39M21.62%800.39K
Operating profit 16.50%1.17B17.00%732.55M16.55%304.87M17.83%1.18B18.44%1.01B21.66%626.09M24.74%261.58M8.38%1B8.74%848.89M6.17%514.63M
Add:Non operating Income 302.70%2.56M1,610.39%1.84M278.31%1.82M166.72%6.75M-40.39%635.76K-122.14%-122.09K-3,940.42%-1.02M-17.46%2.53M-10.05%1.07M-40.60%551.55K
Less:Non operating expense 305.34%21.56M236.80%13.41M238.16%6.96M27.09%20.45M-8.23%5.32M3.89%3.98M42.44%2.06M22.29%16.09M-34.05%5.79M-48.68%3.83M
Total profit 15.15%1.15B15.92%720.99M15.95%299.74M18.06%1.17B18.55%1B21.64%621.99M24.15%258.5M8.09%989.91M9.19%844.16M6.94%511.35M
Less:Income tax cost 15.76%135.86M21.70%94.42M5.31%35.1M22.38%134.4M8.36%117.36M14.05%77.58M55.13%33.33M-6.74%109.82M5.75%108.31M0.87%68.02M
Net profit 15.07%1.02B15.09%626.57M17.53%264.64M17.52%1.03B20.05%883.41M22.80%544.41M20.58%225.17M10.28%880.09M9.72%735.85M7.93%443.32M
Net profit from continuing operation 15.07%1.02B15.09%626.57M17.53%264.64M17.52%1.03B--883.41M22.80%544.41M--225.17M10.28%880.09M----7.93%443.32M
Less:Minority Profit -60.33%-3.57M-696.52%-2.35M71.48%-643.47K87.05%-2.67M63.03%-2.23M92.95%-294.62K-15.80%-2.26M-8,547.33%-20.62M-168.95%-6.02M-2,340.01%-4.18M
Net profit of parent company owners 15.18%1.02B15.46%628.92M16.64%265.28M15.12%1.04B19.38%885.64M21.72%544.7M20.53%227.43M12.90%900.71M10.25%741.87M8.91%447.5M
Earning per share
Basic earning per share 14.77%1.0114.81%0.6213.04%0.2615.73%1.0318.92%0.8822.73%0.5421.05%0.2312.66%0.8910.48%0.747.32%0.44
Diluted earning per share 14.77%1.0114.81%0.6213.04%0.2615.73%1.0318.92%0.8822.73%0.5421.05%0.2312.66%0.8910.48%0.747.32%0.44
Other composite income -395.00%-6.35M151.94%2.15M
Other composite income of parent company owners -------------395.00%-6.35M------------151.94%2.15M--------
Total composite income 15.07%1.02B15.09%626.57M17.53%264.64M16.51%1.03B20.05%883.41M22.80%544.41M20.58%225.17M11.13%882.24M9.72%735.85M7.93%443.32M
Total composite income of parent company owners 15.18%1.02B15.46%628.92M16.64%265.28M14.14%1.03B19.38%885.64M21.72%544.7M20.53%227.43M13.76%902.86M10.25%741.87M8.91%447.5M
Total composite income of minority owners -60.33%-3.57M-696.52%-2.35M71.48%-643.47K87.05%-2.67M63.03%-2.23M92.95%-294.62K-15.80%-2.26M-8,547.33%-20.62M-168.95%-6.02M-2,340.01%-4.18M
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions ------Unqualified opinion------Unqualified opinion----
Auditor ------Lixin Certified Public Accountants (Special General Partnership)------Lixin Certified Public Accountants (Special General Partnership)----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Top CN Stock Gainers
Symbol Price % Chg
KAYO MOTOR
834058
38.58 +29.99%
Zhejiang Zoenn Design
300901
14.86 +20.03%
Zhejiang Meorient Commerce & Exhibition Inc.
300795
22.36 +20.02%
Fujian Zitian Media Technology
300280
22.18 +20.02%
Zhejiang Prulde Electric Appliance
301353
36.46 +20.01%

See the daily top gainer.

Investment Theme Pharmaceutical E-commerce
Pharmaceutical E-commerce
Intraday-1.88%